Washington, D.C. — The Trump administration is poised to publish a controversial report this month, which may suggest a link between the use of acetaminophen, commonly known as Tylenol, during pregnancy and the development of autism spectrum disorder (ASD). This initiative has raised eyebrows due to the dubious scientific backing for these claims.

Health and Human Services Secretary Robert F. Kennedy Jr. is at the center of this unfolding situation, having previously made various unverified statements about autism. Kennedy has vowed to delve into the causes of the disorder, but his approach has already garnered criticism from the medical community.

While the agency has confirmed that it is drafting the report, officials have refrained from disclosing specific conclusions, calling any attempts to predict its content speculative. However, experts emphasize that there is no credible evidence linking acetaminophen to autism, nor supporting the idea that leucovorin, a derivative of folic acid, can prevent the disorder.

Medical authorities, including the Society for Maternal-Fetal Medicine, advocate for the safety of acetaminophen when used during pregnancy, particularly for managing pain and fever. They warn that ignoring fever in early pregnancy can pose serious risks, such as miscarriage and developmental issues.

Dr. Alycia Halladay, chief science officer at the Autism Science Foundation, criticized oversimplifying autism’s causes to a single factor, noting that numerous genes have been associated with the disorder. The foundation has termed any perceived association between acetaminophen and autism as premature and unsupported by consistent scientific research.

While a few limited studies hinted at a connection between fetal exposure to acetaminophen and a rise in diagnoses of ASD and attention-deficit hyperactivity disorder (ADHD), a larger NIH-funded investigation conducted by U.S. and Swedish scientists found no substantial risk involved.

Prior to the publication of the NIH findings, a U.S. District Court had already arrived at a similar conclusion in a product liability case involving acetaminophen.

Leucovorin, which is sometimes prescribed off-label as a treatment for autism, is derived from the vitamin B9 family and typically used to address specific deficiencies often caused by cancer treatments. Its utility stems from theories suggesting that a metabolic variance in some individuals with autism may hinder folic acid from effectively reaching the brain.

Folic acid is crucial for both brain and nervous system development, which is why pregnant women are commonly encouraged to take supplements containing it. Though a deficiency poses risks for neural tube defects, the link between folate levels and autism remains uncertain.

The Autism Science Foundation has stated that while there are preliminary studies indicating a potential risk between low folate levels during pregnancy and autism, the research is still in its infancy and further investigations are crucial to draw any definitive conclusions.